 |
|
|
| |
Comparison of Population Genotype and Ultradeep Sequencing Results from Subjects with Virologic Failure in ARIES: Impact of Low-abundance HIV Variants on Outcome
|
| |
| |
Reported by Jules Levin ICAAC Chicago 2011Sept 17-20
Lisa Ross1, Kathleen Squires2, Benjamin Young3, Edwin DeJesus4, Nicholas Bellos5, Daniel Murphy6, Henry Zhao1, Brian Wine1, Joseph Horton1, Mark Shaefer7
1GlaxoSmithKline, RTP, NC, USA; 2Thomas Jefferson Univ., Philadelphia, PA,USA; 3Rocky Mountain CARES/DIDC, Denver, CO, USA; Health Connections International, Amsterdam, Netherlands; 4Orlando Immunology Ctr., Orlando, FL, USA; 5SW Infectious Disease Assoc., Dallas, TX, USA; 6Clinique Medicale L'Actuel, Montreal, Canada; 7ViiV Healthcare, RTP, NC, USA
References
1. Squires KE, etal. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010 Mar-Apr;11(2):69-79.
2. Squires KE, etal. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010 24 (13):2019-2027.
|
| |
|
|
|
|
|
